W

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

Business Management
Share
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Canadian ‘crypto king’ case to go to jury as criminal trial winds down

Aiden Pleterski, facing fraud charges in Canada over his alleged role in a digital asset Ponzi scheme, said that he was innocent at closing.…

Bitcoin-backed mortgages are coming to Canada, but borrowers are still unaware of the cost

Prospective borrowers face collateral liquidation risks if bitcoin prices drop, though APX said property and crypto collateral will be handled distinctly.…

Chipotle expects modestly higher sales this year as drive-thru ‘Chipotlanes’ come to more stores

The fastcasual chain says menuprice increases helped results. It also noted rising beef costs and “higher protein usage” as people try to find ways to pack…

ServiceNow’s stock slides as earnings miss clouds a raised AI outlook

Even with an uptick in multimilliondollar AI deals, ServiceNow’s earnings results weren’t enough to win over software skeptics Source：MarketWatch

Source：https://www.marketwatch.com/story/adding-lillys-new-drug-to-zepbound-helped-people-lose-up-to-23-of-their-weight-but-there-were-more-side-effects-b7b7c6c0